The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, Schroder Adveq and the European ...
<强> OXFORD,英国,2020年6月23日/美通社B3C金宝搏官网mg / - STRONG> Vaccitech有限公司 A>,临床阶段的生物制药企业,开发免疫疗法来治疗和预防感染性疾病和癌症,今天宣布,它已投放的第一人,在1期临床研究,调查了VTP-300黄金的安全性和免疫原性在健康参加者和患有慢性乙型肝炎病毒(HBV)谁是病毒口服抗病毒药物抑制。的VTP-300原包括Vaccitech的黑猩猩腺病毒牛津1(ChAdOx1),非复制的病毒载体递送3全长HBV抗原刺激剧烈抗体和混合...
PRAGUE, Czech Republic, June 22, 2020 / B3C newswire / -- SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models. The data were presented in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
“SO-C101 is a highly promising modality in immuno-oncology given its ability to mobilize the two most important cell types driving anti-cancer immune responses, NK cells and CD8+ T cells. ...
HEIDELBERG, Germany, June 22, 2020 / B3C newswire / -- 25 years ago, on 20 June 1995, RauCon introduced a completely new category of partnering event: just business deals, no lectures, no company presentations, no keynotes, no stunts or similar distractions. The European Pharma Licensing Exchange was born, euroPLX for short. It was the world’s first and still is the leading partnering event focused on pharma business opportunities.
On its 25-years anniversary and more than 70 successful euroPLX events later, RauCon launched the next new category of pharma partnering: the Marketplace for Pharma Business Opportunities.
...
MUNICH, Germany, June 16, 2020 / B3C newswire / -- arivis , a software provider for visualization, analysis, and management of big image data, announces the new VisionVR 3.2, which now enables users to simultaneously experience 3D and 4D image volumes and surfaces in an immersive environment.
Meet collaborators in VR
Users of arivis VisionVR can meet in a virtual environment and work together on the same dataset. The new collaboration functionality includes:
PRAGUE, Czech Republic, June 15, 2020 / B3C newswire / -- SOTIO , a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.
Poster presentation details
Poster title: | SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent mannerSO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner | ||
Abstract: | 6686 / 2 | ||
Session: | Session PO.IM02.20 - Immunomodulatory ...
HOUSTON, USA, June 12, 2020 / B3C newswire / -- ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays a role in the regulation of blood clotting and inflammation. In animal models of stroke, 3K3A-APC has helped prevent bleeding caused by tPA, the only drug currently indicated for the treatment of acute ischemic stroke. The ... Keeping patients safe and improving quality of care – anytime and anywhere HANNOVER, Germany, June 08, 2020 / B3C newswire / -- Implandata Ophthalmic Products GmbH , a digital health company, announces the launch of its web-based EYEMATE IOP-Tracking Service for remote monitoring and management of glaucoma care. The EYEMATE IOP-Tracking Service is the world’s first solution to provide eye doctors with Intra-Ocular Pressure (IOP) measurements collected 24/7/365 under patients’ normal life conditions. Prof. Kaweh Mansouri, MD, Ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland and Chief Medical Officer of Implandata explains: “Remote IOP monitoring provides immediate alert in case the therapy ... KIEL, Germany, June 05, 2020 / B3C newswire / -- Effective today, Cellbox Solutions GmbH announces the appointment of former Head of Biosolutions R&D from Lonza Pharma and Biotech, Dr. Herbert A. Mueller-Hartmann, as the new Head of Research and Development. Dr. Mueller-Hartmann will be continuing on the successful work of Dr. Hans-Otto Nagels. Wolfgang Kintzel, CEO of Cellbox Solutions, commented: “As Cellbox Solutions enters into its next phase of growth, it is with great pleasure that we announce Herbert as our new Head of R&D. Herbert brings with him extensive experience and a strong record for developing significant ... POMEZIA, Italy, May 28, 2020 / B3C newswire / -- Advent Srl , an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222). The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford, England. Following a long history of partnership, including the announcement on 7 February of an agreement between The Jenner Institute and IRBM’s Advent to manufacture ChAdOx1 nCoV-19, Advent has now manufactured ... <强>莱顿,荷兰,May 26, 2020 / B3C newswire / -- SeraNovo B.V. today announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilising its proprietary Deep Eutectic Solvent (DES) formulation platform , SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and ... DEQING, China, May 21, 2020 / B3C newswire / -- Shuwen Biotech Co. Ltd. , a China-based leader in innovative diagnostics announced today the peer-reviewed publication of data highlighting the potential of its breakthrough point-of-care test in rapidly diagnosing Preeclampsia among women who are admitted to the hospital. The paper, entitled “ Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins ”, was written by collaborators from China Medical University's Shengjing Hospital and Columbia University Medical Center in New York and demonstrates the ability of the test to detect preeclampsia at a high level of accuracy in women admitted to the hospital for any reason. The findings included ...
|